Semaglutide

GLP-1 (SM) is a synthetic analog of glucagon-like peptide-1, the incretin peptide released from intestinal L-cells. The native sequence is cleaved within minutes by dipeptidyl peptidase-4, and analogs in this class are built around that single problem: a substitution at the DPP-4 cleavage site, plus a fatty-acid chain attached through a linker that promotes reversible albumin binding and slows renal clearance. The result is a peptide closely homologous to native GLP-1 but far more persistent in an assay.

Shipped as a 20 mg lyophilized powder in a sealed glass vial. Listed under its coded designation, consistent with how this catalog handles compounds in this class. Supplied for laboratory research use only.

The incretin field is large and the receptor is well characterized. Areas of study include:

• GLP-1 receptor activation — a class B GPCR signaling through cAMP and protein kinase A, measured in cell-based reporter assays.
• Biased agonism and receptor internalization — why different analogs at the same receptor produce different trafficking profiles.
• Protease resistance — DPP-4 cleavage kinetics for the modified versus native sequence.
• Albumin-binding pharmacokinetics — how fatty-acid acylation extends circulating half-life.
• Islet-cell physiology and the incretin axis in preclinical models.
• Structure-activity relationships across acylated peptide analogs.

These are areas of scientific study. We make no claim about outcomes in any organism, and this listing is not a substitute for a prescribed medicine.